Vaccine development against Leishmania donovani

Frontiers in Immunology

Volumn 3, Issue MAY, 2012, Pages

  Das, Amrita ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

immunoprophylaxis; kala azar; Leishmania donovani; Vaccines; Visceral leishmaniasis

Indexed keywords

EID: 84866654610     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00099     Document Type: Review

References (295)

1. Abdelhak, S., Louzir, H., Timm, J., Blel, L., Benlasfar, Z., Lagranderie, M., Gheorghiu, M., Dellagi, K., and Gicquel, B. (1995). Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 141, 1585-1592.
2. Addy, M., and Nandy, A. (1992). Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull. World Health Organ. 70, 341-346
3. Afrin, F., and Ali, N. (1997). Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect. Immun. 65, 2371-2377.
4. Afrin, F., Anam, K., and Ali, N. (2000). Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes. J. Parasitol. 86, 730-735.
5. Afrin, F., Rajesh, R., Anam, K., Gopinath, M., Pal, S., and Ali, N. (2002). Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect. Immun. 70, 6697-6706.
6. Agallou, M., Margaroni, M., and Karagouni, E. (2011). Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Vaccine 29, 5053-5064.
7. Aguilar-Be, I., da Silva Zardo, R., Paraguai de Souza, E., BorjaCabrera, G. P., Rosado-Vallado, M., Mut-Martin, M., García-Miss Mdel, R., Palatnik de Sousa, C. B., and Dumonteil, E. (2005). Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect. Immun.73, 812-819.
8. Ahuja, S. S., Reddick, R. L., Sato, N., Montalbo, E., Kostecki, V., Zhao, W., Dolan, M. J., Melby, P. C., and Ahuja, S. K. (1999). Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J. Immunol. 163, 3890-3897
9. Akbari, O., Panjwani, N., Garcia, S., Tascon, R., Lowrie, D., and Stockinger, B. (1999). DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189, 169-178.
10. Akuffo, H., Maasho, K., and Howe, R. (1993). Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells. Clin. Exp. Immunol. 94, 516-521.
11. Alexander, J., Carter, K. C., Al-Fasi, N., Satoskar, A., and Brombacher, F. (2000). Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30, 2935-2943.
12. Ali, N., and Afrin, F. (1997). Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. J. Parasitol. 83, 70-75.
13. Alvar, J.,Yactayo, S., and Bern, C. (2006). Leishmaniasis and poverty. Trends Parasitol. 22, 552-557.
14. Anam, K.,Afrin, F., Banerjee, D., Pramanik, N., Guha, S. K., Goswami, R. P., Gupta, P. N., Saha, S. K., and Ali, N. (1999a). Immunoglobulin subclass distribution and diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in Indian kala-azar patients. Clin. Diagn. Lab. Immunol. 6, 231-235.
15. Anam, K., Afrin, F., Banerjee, D., Pramanik, N., Guha, S. K., Goswami, R. P., Saha, S. K., and Ali, N. (1999b). Differential decline in Leishmania membrane antigenspecific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy. Infect. Immun. 67, 6663-6669.
16. Anderson,C. F.,Stumhofer,J. S.,Hunter, C. A., and Sacks, D. (2009). IL27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J. Immunol. 183, 4619-4627.
17. Ansari, N. A., Kumar, R., Gautam, S., Nylén, S., Singh, O. P., Sundar, S., and Sacks, D. (2011). IL27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J. Immunol. 186, 3977-3985.
18. Armijos, R. X., Weigel, M. M., Hidalgo, A., Cevallos, W., and Correa, J. (2004). Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 22, 1320-1326.
19. Armitage, R. J., MacDuff, B. M., Eisenman, J., Paxton, R., and Grabstein, K. H. (1995). IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol. 154, 483-490.
20. Atta, A. M., D'Oliveira, C. J., Atta, M. L., Almeida, R. P., and Carvalho, E. M. (1998). Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis. Am. J. Trop. Med. Hyg. 59, 426-430.
21. Babaloo, Z., Kaye, P. M., and Eslami, M. B. (2001). Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans. R. Soc. Trop. Med. Hyg. 95, 85-88.
22. Bacellar, O., Brodskyn, C., Guerreiro, J., Barral-Netto, M., Costa, C. H., Coffman, R. L., Johnson, W. D., and Carvalho, E. M. (1996). Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J. Infect. Dis. 173, 1515-1518.
23. Badaro, R., Falcoff, E., Badaro, F. S., Carvalho, E. M., Pedral-Sampaio, D., Barral, A., Carvalho, J. S., BarralNetto, M., Brandely, M., Silva, L., Bina, J. C., Teixeira, R., Falcoff, R., Rocha, H., Ho, J. L., and Johnson, W. D. Jr. (1990). Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N. Engl.J.Med.322, 16-21.
24. Badaro, R., and Johnson, W. D. Jr. (1993). The role of interferongamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J. Infect. Dis. 167, 13-17.
25. Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252.
26. Barbier, D., Demenais, F., Lefait, J. F., David, B., Blanc, M., Hors, J., and Feingold, N. (1987). Susceptibility to human cutaneous leishmaniasis and HLA, Gm, Km markers. Tissue Antigens 30, 63-67.
27. Barh, D., Misra, A. N., and Kumar, A. (2010). In silico identification of dual ability of N. gonorrhoeae ddl for developing drug and vaccine against pathogenic Neisseria and other human pathogens. J. Proteomics Bioinform. 3, 082-090.
28. Barral-Netto, M., Barral, A., Brownell, C. E., Skeiky, Y. A., Ellingsworth, L. R., Twardzik, D. R., and Reed, S. G. (1992). Transforming growth factorbeta in leishmanial infection: a parasite escape mechanism. Science 257, 545-548.
29. Basu, R., Bhaumik, S., Basu, J. M., Naskar, K., De, T., and Roy, S. (2005). Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1and Th2-like responses in visceral leishmaniasis. J. Immunol. 174, 7160-7171.
30. Basu, R., Bhaumik, S., Haldar, A. K., Naskar, K., De, T., Dana, S. K., Walden, P., and Roy, S. (2007). Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic Tlymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect. Immun. 75, 5956-5966.
31. Belkaid, Y., Mendez, S., Lira, R., Kadambi, N., Milon, G., and Sacks, D. (2000). A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 165, 969-977.
32. Beverley, S. M., and Turco, S. J. (1998). Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite Leishmania. Trends Microbiol. 6, 35-40.
33. Bhardwaj, S., Vasishta, R. K., and Arora, S. K. (2009). Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis. Exp. Parasitol. 121, 29-37.
34. Bhaumik, S., Basu, R., Sen, S., Naskar, K., and Roy, S. (2009). KMP-11DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 27, 1306-1316.
35. Bhowmick, S., and Ali, N. (2009). Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PLoS ONE 4, e5820. doi:10.1371/journal.pone.0005820
36. Bhowmick, S., Mazumdar, T., and Ali, N. (2009). Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. Infect. Immun. 77, 1514-1523.
37. Bhowmick, S., Mazumdar, T., Sinha, R., and Ali, N. (2010). Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. J. Control Release 141, 199-207.
38. Bhowmick,S.,Ravindran,R.,and Ali,N. (2007). Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25, 6544-6556.
39. Bhowmick, S., Ravindran, R., and Ali, N. (2008). gp63 in Stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect. Immun. 76, 1003-1015.
40. Blackwell,J.M.(1996). Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 112 (Suppl.), S67-S74.
41. Blackwell, J. M., Mohamed, H. S., and Ibrahim, M. E. (2005). Genetics and visceral leishmaniasis in the Sudan: seeking a link. Trends Parasitol. 20, 268-274.
42. Bocarsly, P., Tomai, M. A., and Vasilakos, J. P. (2002). Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 218, 74-86.
43. Bogdan, C., Gessner, A., Solbach, W., and Röllinghoff, M. (1996). Invasion, control and persistence of Leishmania parasites. Curr. Opin. Immunol. 84, 517-525.
44. Bogdan, C., and Rollinghoff, M. (1998). The immune response to Leishmania: mechanisms of parasite control and evasion. Int. J. Parasitol. 28, 121-134.
45. Borja-Cabrera, G. P., Correia Pontes, N. N., da Silva,V. O., Paraguai de Souza, E., Santos, W. R., Gomes, E. M., Luz, K. G., Palatnik, M., and Palatnik de Sousa, C. B. (2002). Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 20, 3277-3284.
46. Bourgeois, C., Veiga-Fernandes, H., Joret, A. M., Rocha, B., and Tanchot, C. (2002). CD8 lethargy in the absence of CD4 help. Eur. J. Immunol. 32, 2199-2207.
47. Bourguin, I., Moser, M., Buzoni-Gatel, D., Tielemans, F., Bout, D., Urbain, J., and Leo,O. (1998). Murine dendritic cells pulsed in vitro with Toxoplasma gondii antigens induce protective immunity in vivo. Infect. Immun. 66, 4867.
48. Bradley, D. J. (1974). Letter: genetic control of natural resistance to Leishmania donovani. Nature 250, 353-354.
49. Brandonisio, O., Spinelli, R., and Pepe, M. (2004). Dendritic cells in Leishmania infection. Microbes Infect. 6, 1402-1409.
50. Bray, R. S. (1976). "Immunodiagnosis of leishmaniasis," in Immunology of Parasite Infection, eds S. Cohen and E. H. Sadun (Oxford:Blackwell Scientific Publications), 65-66.
51. Breton, M., Tremblay, M. J., Ouellette, M., and Papadopoulou, B. (2005). Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun. 73, 6372-6782.
52. Bruhn, K. W., Birnbaum, R., Haskell, J., Vanchinathan, V., Greger, S., Narayan, R., Chang, P. L., Tran, T. A., Hickerson, S. M., Beverley, S. M., Wilson, M. E., and Craft, N. (2012). Killed but metabolically active Leishmania infantum as a novel wholecell vaccine for visceral leishmaniasis. Clin. Vaccine Immunol. 19, 490-498.
53. Buates, S., and Matlashewski, G. (1999). Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. 179, 1485-1494.
54. Bucheton, B., Abel, L., Kheir, M. M., Mirgani,A.,El-Safi,S. H.,Chevillard, C., and Dessein, A. (2003). Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. Genes Immun. 4, 104-109.
55. Bucheton, B., Kheir, M. M., El-Safi, S. H., Hammad, A., Mergani, A., Mary, C., Abel, L., and Dessein, A. (2002). The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. Microbes Infect. 14, 1449-1457.
56. Caldas, A., Favali, C., Aquino, D., Vinhas, V., van Weyenbergh, J., Brodskyn, C., Costa, J., Barral-Netto, M., and Barral, A. (2005). Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect. Dis. 5, 113. doi:10.1186/1471-2334-5-113
57. Carrión, J., Folgueira, C., Soto, M., Fresno, M., and Requena, J. M. (2011). Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. Parasit. Vectors 4, 150.
58. Carrión, J., Nieto, A., Iborra, S., Iniesta, V., Soto, M., Folgueira, C., Abanades, D. R., Requena, J. M., and Alonso, C. (2006). Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol. 28, 173-183.
59. Carson, W. E., Giri, J. G., Lindermann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., and Caligiuri, M. A. (1994). Interleukin-(IL)-15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395-1403.
60. Carson, W. E., Ross, M. E., Baiocchi, R. A., Marien, M. J., Boiani, N., Grabstein, K., and Caligiuri, M. A. (1995). Endogenous production of interleukin-15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J. Clin. Invest. 96, 2578-2582.
61. Carter, K. C., Henriquez, F. L., Campbell, S. A., Roberts, C. W., Nok, A., Mullen, A. B., and McFarlane, E. (2007). DNA vaccination against the parasite enzyme gamma glutamylcysteinesynthetase confers protection against Leishmania donovani infection. Vaccine 25, 4502-4509.
62. Carvalho, E. M., Bacellar, O., Brownell, C., Regis, T., Coffman, R. L., and Reed, S. G. (1994). Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152, 5949-5956.
63. Chakravarty, J., Kumar, S., Trivedi, S., Rai, V. K., Singh, A., Ashman, J. A., Laughlin, E. M., Coler, R. N., Kahn, S. J., Beckmann, A. M., Cowgill, K. D.,Reed,S. G.,Sundar,S.,and Piazza, F. M. (2011). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29, 3531-3537.
64. Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., Alvar, J., and Boelaert, M. (2007). Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5, 873-882.
65. Chenik, M., Louzir, H., Ksontini, H., Dilou, A., Abdmouleh, I., and Dellagi, K. (2006). Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major. Vaccine 24, 2521-2529.
66. Clarêncio, J., de Oliveira, C. I., Favali, C., Medina, O., Caldas, A., Costa, C. H., Costa, D. L., Brodskyn, C., Barral, A., and Barral-Netto, M. (2009). Could the lower frequency of CD8+CD18+CD45RO+ lymphocytes be biomarkers of human VL? Int. Immunol. 212, 137-144.
67. Coler, R. N., Yasuyuki, G., Bogatzki, L., Raman, V., and Reed, S. G. (2007). Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4 T cells. Infect. Immun. 75, 4648-4654.
68. Corr, M., Lee, D. J., Carson, D. A., and Tighe, H. (1996). Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184, 1555-1560.
69. Da Matta, V. L., Hoshino-Shimizu, S., Dietze, R., and Corbett, C. E. (2000). Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis. J. Clin. Lab. Anal. 14, 5-12.
70. Davies, C. R., and Mazloumi Gavgani, A. S. (1999). Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran. Parasitology 119, 247-257.
71. DE Oliveira Gomes, D. C., DA Silva Costa Souza, B. L., DE Matos Guedes, H. L., Lopes, U. G., and Rossi-Bergmann, B. (2011). Intranasal immunization with LACK-DNA promotes protective immunity in hamsters challenged with Leishmania chagasi. Parasitology 138, 1892-1897.
72. Demant, P., Lipoldova, M., and Svobodova, M. (1996). Resistance to Leishmania major in mice. Science 274, 1392-1393.
73. Dereure, J., El-Safi, S. H., Bucheton, B, Boni, M., Kheir, M. M., Davoust, B., Pratlong, F., Feugier, E., Lambert, M., Dessein, A., and Dedet, J. P. (2003). Visceral leishmaniasis in eastern Sudan: parasite identification in humans and dogs; host-parasite relationships. Microbes Infect. 5, 1103-1108.
74. Desjardins, M., and Descoteaux, A. (1997). Inhibition of phagolysosomal biogenesis by the Leishmania lipophosphoglycan. J. Exp. Med. 185, 2061-2068.
75. Dey, R., Meneses, C., Salotra, P., Kamhawi, S., Nakhasi, H. L., and Duncan, R. (2010). Characterization of a Leishmania stagespecific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence. Mol. Microbiol. 77, 399-414.
76. Dole, V. S., Raj, V. S., Ghosh, A., Madhubala, R., Myler, P. J., and Stuart, K. D. (2000). Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine 19, 423-430.
77. D'Oliveira Junior, A., Costa, S. R., Barbosa, A. B., Orge M de la, G., and Carvalho, E. M. (1997). Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis. Mem. Inst. Oswaldo Cruz 92, 15-20.
78. Dominguez, M., Moreno, I., LopezTrascasa, M., and Torano, A. (2002). Complement interaction with trypanosomatid promastigotes in normal human serum. J. Exp. Med. 195, 451-459.
79. Donaghy, L., Cabillic, F., Corlu, A., Rostan, O., Toutirais, O., GuguenGuillouzo, C., Guiguen, C., and Gangneux, J. P. (2010). Immunostimulatory properties of dendritic cells after Leishmania donovani infection using an in vitro model of liver microenvironment. PLoS Negl. Trop. Dis. 4, e703. doi:10.1371/journal.pntd.0000703
80. Dube, A., Sharma, P., Srivastava, J. K., Misra, A., Naik, S., and Katiyar, J. C. (1998). Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 116(Pt 3), 219-221.
81. Dutta, A., Singh, S. K., Ghosh, P., Mukherjee,R.,Mitter,S.,and Bandyopadhyay, D. (2006). In silico identification of potential therapeutic targets in the human pathogen Helicobacter pylori. In silico Biol. (Gedrukt) 6, 43-47.
82. Encke, J., Bernardin, J., Geib, J., Barbakadze, G., Bujdoso, R., and Stremmel, W. (2006). Genetic vaccination with Flt3-L and GM-CSF as adjuvants: enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis c virus infection. World J. Gastroenterol. 12, 7118-7125.
83. Engwerda, C. R., Ato, M., and Kaye, P. M. (2004). Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol. 20, 524-530.
84. Fakiola, M., Miller, E. N., Fadl, M., Mohamed, H. S., Jamieson, S. E., Francis, R. W., Cordell, H. J., Peacock, C. S., Raju, M., Khalil, E. A., Elhassan, A., Musa, A. M., Silveira, F., Shaw, J. J., Sundar, S., Jeronimo, S. M., Ibrahim, M. E., and Blackwell, J. M. (2011). Genetic and functional evidence implicating DLL1 as the gene that influences susceptibility to visceral leishmaniasis at chromosome 6q27. J. Infect. Dis. 204, 467-477.
85. Favali, C., Tavares, N., Clarêncio, J., Barral, A., Barral-Netto, M., and Brodskyn, C. (2007). Leishmania amazonensis infection impairs differentiation and function of human dendritic cells. J. Leukoc. Biol. 82, 1401-1406.
86. Forgber, M., Basu, R., Roychoudhury, K., Theinert, S., Roy, S., Sundar, S., and Walden, P. (2006). Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS ONE 1, e40. doi:10.1371/journal.pone.0000040
87. Gamboa-León, R., Paraguai de Souza, E., Borja-Cabrera, G. P., Santos, F. N., Myashiro, L. M., Pinheiro, R. O., Dumonteil, E., and Palatnik-deSousa,C. B. (2006). Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.Vaccine 24, 4863-4873.
88. Gantt, K. R., Schultz-Cherry, S., Rodriguez, N., Jeronimo, S. M., Nascimento, E. T., Goldman, T. L., Recker, T. J., Miller, M. A., and Wilson, M. E. (2003). Activation of TGF beta by Leishmania chagasi: importance for parasite survival in macrophages. J. Immunol. 170, 2613-2620.
89. Garg, R., Gupta, S. K., Tripathi, P., Hajela, K., Sundar, S., Naik, S., and Dube, A. (2006). Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human, and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine 24, 2900-2909.
90. Genaro, O., de Toledo, V. P., da Costa, C. A., Hermeto, M. V., Afonso, L. C., and Mayrink, W. (1996). Vaccine for prophylaxis and immunotherapy, Brazil. Clin. Dermatol. 14, 503-512.
91. George-Chandy,A., Mielcarek, N., Nordström, I., Holmgren, J., and Eriksson, K. (2001). Vaccination with Bordetella pertussis-pulsed autologous or heterologous dendritic cells induces a mucosal antibody response in vivo and protects against infection. Infect. Immun. 69, 4120-4124.
92. Ghalib, H. W., Piuvezam, M. R., Skeiky, Y. A., Siddig, M., Hashim, F. A., elHassan, A. M., Russo, D. M., and Reed, S. G. (1993). Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92, 324-329.
93. Ghalib, H. W., Whittle, J. A., Kubin, M., Hashim, F. A., el-Hassan, A. M., Grabstein, K. H., Trinchieri, G., and Reed, S. G. (1995). IL12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. 154, 4623-4629.
94. Ghosh, A., Labrecque, S., and Matlashewski, G. (2001a). Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 19, 3169-3178.
95. Ghosh, A., Zhang, W. W., and Matlashewski, G. (2001b). Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20, 59-66.
96. Ghosh, M., Pal, C., Ray, M., Maitra, S., Mandal, L., and Bandyopadhyay, S. (2003). Dendritic cellbased immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J. Immunol. 170, 5625-5629.
97. Gibson, S. J., Lindh, J. M., Riter, T. R., Gleason, R. M., Rogers, L. M., Fuller, A. E., Oesterich, J. L., Gorden, K. B., Qiu, X., McKane, S. W., Noelle, R. J., Miller, R. L., Kedl, R. M., FitzgeraldBocarsly, P., Tomai, M. A., and Vasilakos, J. P. (2002). Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 218, 74-86.
98. Gillespie, R. D., Mbow, M. L., and Titus, R. G. (2000). The immunomodulatory factors of blood feeding arthropod saliva. Parasite Immunol. 22, 319-331.
99. Gomes, N. A., Gattass, C. R., BarretoDe-Souza, V., Wilson, M. E., and DosReis, G. A. (2000). TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. J. Immunol. 164, 2001-2008.
100. Gomes, D. C., Pinto, E. F., de Melo, L. D., Lima, W. P., Larraga,V., Lopes, U. G., and Rossi-Bergmann, B. (2007). Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. Vaccine 25, 2168-2172.
101. Gomes, R., Teixeira, C., Teixeira, M. J., Oliveira, F., Menezes, M. J., Silva, C., de Oliveira, C. I., Miranda, J. C., Elnaiem, D. E., Kamhawi, S., Valenzuela, J. G., and Brodskyn, C. I. (2008). Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc. Natl. Acad. Sci. U.S.A. 105, 7845-7850.
102. Gradoni, L. (2001). An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet. Parasitol. 100, 87-103.
103. Green, S. J., Meltzer, M. S., Hibbs, J. B. Jr., and Nacy, C. A. (1990). Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J. Immunol. 144, 278-283.
104. Gueirard, P., Laplante, A., Rondeau, C., Milon, G., and Desjardins, M. (2008). Trafficking of Leishmania donovani promastigotes in nonlytic compartments in neutrophils enables the subsequent transfer of parasites to macrophages. Cell. Microbiol. 10, 100-111.
105. Gupta, S. K., Singh, S., Gupta, M. K., Pant, K. K., and Seth, P. K. (2010). Identification of potential targets in Mycoplasma pneumonia through subtractive genome analysis. J. Antivir. Antiretrovir. 2, 038-041.
106. Gupta, S. K., Sisodia, B. S., Sinha, S., Hajela, K., Naik, S., Shasany, A. K., and Dube, A. (2007). Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 7, 816-823.
107. Gurunathan, S., Prussin, C., Sacks, D. L., and Seder, R. A. (1998). Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4, 1409-1415.
108. Gurunathan, S., Sacks, D. L., Brown, D. R., Reiner, S. L., Charest, H., Glaichenhaus, N., and Seder, R. A.(1997). Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186, 1137-1147.
109. Hailu, A., Menon, J. N., Berhe, N., Gedamu, L., Hassard, T. H., Kager, P. A., Olobo, J., and Bretscher, P. A. (2001). Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J. Infect. Dis. 184, 112-115.
110. Handman, E. (2001). Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14, 229-243.
111. Handman,E.,Button,L. L.,and McMaster, R. W. (1990). Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp. Parasitol. 70, 427-435.
112. Handman, E. and Mitchell G. F. (1985). Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc. Natl. Acad. Sci. U.S.A. 82, 5910-5914.
113. Harms,G., Zwingenberger, K., Sandkamp, B., Omena, S., Pedrosa, C., Richter, J., Rosenkaimer, F., Feldmeier, H., and Bienzle, U. (1993). Immunochemotherapy of visceral leishmaniasis: a pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony. J. Interferon Res. 13, 39-41.
114. Hayashi, F., Means, T. K., and Luster, A. D. (2003). Toll-like receptors stimulate human neutrophil function. Blood 10, 2660-2669.
115. Hemmi, H., Kaisho, T., Takeuchi, O., Sato,S.,Sanjo,H.,Hoshino,K.,Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. (2002). Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196-200.
116. Henriquez, F. L., Campbell, S. A., Roberts, C. W., Mullen, A. B., Burchmore, R., and Carter, K. C. (2010). Vaccination with recombinant Leishmania donovani gammaglutamylcysteine synthetase fusion protein protects against L. donovani infection. J. Parasitol. 96, 929-936.
117. Hotez, P. J., Remme, H. F., Buss, P., George, G., Morel, C., and Breman, J. G. (2004). Combating tropical infectious diseases: report of the disease control priorities in developing countries project. Clin. Infect. Dis. 38, 871-878.
118. Huynen, M., Dandekar, T., and Bork, P. (1998). Differential genome analysis applied to the species-specific features of Helicobacter pylori. FEBS Lett. 426, 1-5.
119. Iborra, S., Carrión, J., Anderson, C., Alonso, C., Sacks, D., and Soto, M. (2005). Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infect. Immun. 73, 5842-5852.
120. Ilg, T. (2000). Lipophosphoglycan is not required for infection of macrophages or mice by Leishmania mexicana. EMBO J. 19, 1953-1962.
121. Jaafari, M. R., Badiee, A., Khamesipour, A., Samiei, A., Soroush, D., Kheiri, M. T., Barkhordari, F., McMaster, W. R., and Mahboudi, F. (2007) The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 25, 6107-6117.
122. Jaafari, M. R., Ghafarian, A., FarrokhGisour, A., Samiei, A., Kheiri, M. T., Mahboudi, F., Barkhordari, F.,Khamesipour, A., and McMaster, W. R. (2006). Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24, 5708-5717.
123. Jaffe,C. L.,Rachamim,N.,and Sarfstein, R. (1990). Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J. Immunol. 144, 699-706.
124. Jain, M., and Madhubala, R. (2008). Characterization and localization of ORFF gene from the LD1 locus of Leishmania donovani. Gene 416, 1-10.
125. Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., and Schoenberger, S. P. (2003). CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421, 852-856.
126. Jardim, A., Alexander, J., Teh, H. S., Ou, D. W., and Olafson, R. W. (1990). Immunoprotective Leishmania major synthetic T cell epitopes. J. Exp. Med. 172, 645-648.
127. Joshi, T., Rodriguez, S., Perovic, V., Cockburn, I. A., and Stager, S. (2009). B7-H1 blockade increases survival of dysfunctional CD8+ T cells and confers protection against Leishmania donovani infections. PLoS Pathog. 5, e1000431. doi:10.1371/journal.ppat.1000431
128. Jullien, D., Sieling, P. A., Uyemura, K., Mar, N. D., Rea, T. H., and Modlin, R. L. (1997). IL-15,an immunomodulator of T cell responses in intracellular infection. J. Immunol. 158, 800-806.
129. Kahl, L. P., Lelchuk, R., Scott, C. A., and Beesley, J. (1990). Characterization of Leishmania major antigenliposomes that protect BALB/c mice against cutaneous leishmaniasis. Infect. Immun. 58, 3233-3241.
130. Kaisho, T., and Akira, S. (2000). Critical roles of Toll-like receptors in host defense. Crit. Rev. Immunol. 20, 393-405.
131. Kaisho, T., and Akira, S. (2001). Toll-like receptors and their signaling mechanism in innate immunity. Acta Odontol. Scand. 59, 124-130.
132. Kamogawa, Y., Minasi, L. A., Carding, S. R., Bottomly, K., and Flavell, R. A. (1993). The relationship of IL-4and IFN gamma-producing T cells studied by lineage ablation of IL-4producing cells. Cell 75, 985-995.
133. Kang, D. C., Gopalkrishnan, R. V., Wu, Q., Jankowsky, E., Pyle, A. M., and Fisher, P. B. (2002). mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. U.S.A. 99, 637-642.
134. Karanja, R., Ingonga, J., Mwangi, M., Mwala, D., Lugalia, R., Magambo, J., and Tonui, W. (2011). Immunization with a combination of Leishmania major lipophosphoglycan (LPG) and Phlebotomus duboscqi salivary gland lysates (SGLs) abrogates protective effect of LPG against L. major in BALB/c mice. Afr. J. Health Sci. 18, 1-5.
135. Karplus, T. M., Jeronimo, S. M., Chang, H., Helms, B. K., Burns, T. L., Murray, J. C., Mitchell, A. A., Pugh, E. W., Braz, R. F., Bezerra, F. L., and Wilson, M. E. (2002). Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect. Immun. 70, 6919-6925.
136. Kaur, T., Sobti, R. C., and Kaur, S. (2011a). Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB/c mice. Parasite Immunol. 33, 95-103.
137. Kaur, J., Kaur, T., and Kaur, S. (2011b). Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Acta Trop. 119, 50-56.
138. Kaye, P., and Scott, P. (2011). Leishmaniasis: complexity at the host- pathogen interface. Nat. Rev. Microbiol. 9, 604-615.
139. Kenney, R. T., Sacks, D. L., Gam, A. A., Murray, H. W., and Sundar, S. (1998). Splenic cytokine responses in Indian kala-azar before and after treatment. J. Infect. Dis. 177, 815-818.
140. Khalil, E. A., El Hassan, A. M., Zijlstra, E. E., Mukhtar, M. M., Ghalib, H. W., Musa, B., Ibrahim, M. E., Kamil, A. A., Elsheikh, M., Babiker, A., and Modabber, F. (2000). Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356, 1565-1569.
141. Khalil, E. A., Musa, A. M., Modabber, F., and El-Hassan, A. M. (2006). Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major (BCG) in children: an extended phase II study. Ann. Trop. Paediatr. 26, 357-361.
142. Khamesipour, A., Dowlati, Y., Asilian, A., Hashemi Fesharki, R., Javadi, A., Noazin, S., and Modabber, F. (2005). Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23, 3642-3648.
143. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., and Trinchieri, G. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med.170, 827-845.
144. Kobukai, S., Kremers, G. J., Cobb, J. G., Baheza, R., Xie, J., Kuley, A., Zhu, M., and Pham, W. (2011). Induction of antitumor immunity by dendritic cells loaded with membrane-translocating mucin 1 Peptide antigen. Transl. Oncol. 4, 1-8.
145. Kubar, J., and Fragaki, K. (2005). Recombinant DNA-derived Leishmania proteins: from the laboratory to the field. Lancet. Infect. Dis. 5, 107-114.
146. Kumari,S.,Samant,M.,Misra,P.,Khare, P., Sisodia, B., Shasany, A. K., and Dube, A. (2008a). Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers longlasting protection against experimental visceral leishmaniasis. Vaccine 26, 5700-5711.
147. Kumari, S., Samant, M., Khare, P., Sundar, S., Sinha, S., and Dube, A. (2008b). Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa. Vaccine 26, 4813-4818.
148. Kushawaha, P. K., Gupta, R., Sundar, S., and Dube, A. (2011). Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-? and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J. Immunol. 187, 6417-6427.
149. Lamb,J. R.,Zanders,E. D.,Lake,P.,Webster, R. G., Eckels, D. D.,Woody, J. N., Green, N., Lerner, R. A., and Feldmann,M. (1984). Inhibition of T cell proliferation by antibodies to synthetic peptides. Eur. J. Immunol. 14, 153-157.
150. Lara, M. L., Layrisse, Z., Scorza, J. V., Garcia, E., Stoikow, Z., Granados, J., and Bias, W. Immunogenetics of human American cutaneous leishmaniasis. (1991). Study of HLA haplotypes in 24 families from Venezuela. Hum. Immunol. 30, 129-135.
151. Larsen, M. H., Biermann, K., Chen, B., Hsu, T., Sambandamurthy, V. K., Lackner, A. A., Aye, P. P., Didier, P., Huang, D., Shao, L., Wei, H., Letvin, N. L., Frothingham, R., Haynes, B. F., Chen, Z. W., and Jacobs, W. R. Jr. (2009). Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27, 4709-4717.
152. Li, J., Hunter, C. A., and Farrell, J. P. (1999). Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J. Immunol. 162, 974-979.
153. Lima, K. M., Aparecida dos Santos, A., Rodrigues, J. M. Jr., and Silva, C. L. (2004). Vaccine adjuvant: it makes the difference. Vaccine 22, 2374-2379.
154. Lodge, R., Diallo, T. O., and Descoteaux, A. (2006). Leishmania donovani lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane. Cell. Microbiol. 8, 1922-1931.
155. Macedo, A. B., Sánchez-Arcila, J. C., Schubach, A. O., Mendonça, S. C., Marins-Dos-Santos, A., de Fatima Madeira, M., Gagini, T., Pimentel, M. I., and De Luca, P. M. (2012). Multifunctional CD4+ T cells in patients with American cutaneous leishmaniasis. Clin. Exp. Immunol. 167, 505-513.
156. Madagi, S., Patil, V. M., Sadegh, S., Singh, A. K., Garwal, B., Banerjee, A., Talambedu, U., and Bhattacharjee,B. (2011). Identification of membrane associated drug targets in Borrelia burgdorferi ZS7subtractive genomics approach. Bioinformation 6, 356-359.
157. Mandage, R. H., and Wadnerkar, A. S. (2010). Subtractive genomics approach to identify potential therapeutic targets in Leishmania donovani. Int. J. Pharm. Bio Sci. 1, 1-7.
158. Martinon, F., and Tschopp, J. (2005). NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 26, 447-454.
159. Masih, S., Arora, S. K., and Vasishta, R. K. (2011). Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis. Exp. Parasitol. 129, 55-64.
160. Mazumder, T., Anam, K., and Ali, N. (2004). A mixed Th1/Th2 response elicited by a lip osomalformulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22, 1162-1171.
161. Mazumder, S., Maji, M., and Ali, N. (2011a). Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. PLoS Negl. Trop. Dis. 5,e1429. doi:10.1371/journal.pntd.0001429
162. Mazumder, S., Maji, M., Das, A., and Ali, N. (2011b). Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS ONE 6, e14644. doi:10.1371/journal.pone.0014644
163. Mazumder, S., Ravindran, R., Banerjee, A., and Ali, N. (2007). Non-coding pDNAbearingimmunostimula-tory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice. Vaccine 25, 8771-8781.
164. McConville, M. J., Bacic, A., Mitchell, G. F., and Handman, E. (1987). Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc. Natl. Acad. Sci. U.S.A. 84, 8941-8945.
165. McShane, H., Behboudi, S., Goonetilleke, N., Brookes, R., and Hill, A. V. (2002). Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8 (+)and CD4(+)-T-cell epitopes from antigen 85A. Infect. Immun. 70, 1623-1626.
166. McSorley, S. J., Xu, D., and Liew, F. Y. (1997). Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infect. Immun. 65, 171-178.
167. Meddeb-Garnaoui, A., Toumi, A., Ghelis, H., Mahjoub, M., Louzir, H., and Chenik, M. (2010). Cellular and humoral responses induced by Leishmania histone H2B and its divergent and conserved parts in cutaneous and visceral leishmaniasis patients, respectively. Vaccine 28, 1881-1886.
168. Melby, P., Ogden, G. B., Flores, H. A., Zhao, W., Geldmacher, C., Biediger, N. M., Ahuja, S. K., Uranga, J., and Melendez, M. (2000). Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect. Immun. 68, 5595-5602.
169. Melby, P. C., Chandrasekar, B., Zhao, W., and Coe, J. E. (2001a). The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 166, 1912-1920.
170. Melby, P. C., Yang, J., Zhao, W., Perez, L. E., and Cheng, J. (2001b). Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69, 4719-4725.
171. Mellman, I., and Steinman, R. M. (2001). Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258.
172. Mendez, S., Tabbara, K., Belkaid, Y., Bertholet, S., Verthelyi, D., Klinman, D., Seder, R. A., and Sacks, D. L. (2003). Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect. Immun. 71, 5121-5129.
173. Milano, S., Di Bella, G., D'Agostino, P., Barbera, C., Caruso, R., La Rosa, M., Ferlazzo, V., Vitale, G., La Russa, C., Gambino, G., Chifari, N., Mansueto, S., and Cillari, E. (2002). IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin. Exp. Immunol. 127, 360-365.
174. Misra, A., Dube, A., Shrivastava, B., Sharma, P., Shrivastava, J. K., and Katiyar, J. C. (2001). Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 19, 3485-3492.
175. Mizbani, A., Taheri, T., Zahedifard, F., Taslimi, Y., Azizi, H., Azadmanesh, K., Papadopoulou, B., and Rafati, S. (2009). Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28, 53-62.
176. Mizbani, A., Taslimi, Y., Zahedifard, F., Taheri, T., and Rafati, S. (2011). EffectofA2geneoninfectivityof the nonpathogenic parasite Leishmania tarentolae. Parasitol. Res. 109, 793-799.
177. Mohamed, H. S., Ibrahim, M. E., Miller, E. N., Peacock, C. S., Khalil, E. A., Cordell, H. J., Howson, J. M., El Hassan, A. M., Bereir, R. E., and Blackwell, J. M. (2003). Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1. Genes Immun. 4, 351-355.
178. Mohamed, H. S., Ibrahim, M. E., Miller, E. N., White, J. K., Cordell, H. J., Howson, J. M., Peacock, C. S., Khalil, E. A., El Hassan, A. M., and Blackwell, J. M. (2004). SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. Eur. J. Hum. Genet. 12,66-74. Mohebali, M., Khamesipour, A., Mobedi, I., Zarei, Z., and HashemiFesharki, R. (2004). Double blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine 22, 4097-4100.
179. Mohebali M., Khamesipour, A., Mobedi, I., Zarei, Z., and HashemiFesharki, R. (2004). Double blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine 22, 4097-4100.
180. Moll,H.,and Berberich,C. (2001). Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis. Immunobiology 204, 659-666.
181. Momeni, A. Z., and Aminjavaheri, M. (1994). Clinical picture of cutaneous leishmaniasis in Isfahan, Iran. Int. J. Dermatol. 33, 260-265.
182. Momeni, A. Z., Jalayer, T., Emamjomeh, T., Khamesipour,A., Zicker, F., Ghassemi, R. L., Dowlati, Y., Sharifi, I., Aminjavaheri, M., Shafiei, I., Alimohammadian, M. H., HashemiFesharki, R., Nasseri, K., Godal, T., Smith, P. G., and Modabber, F. (1999). A randomized double blind controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17, 466-472.
183. Morris, R. V., Shoemaker, C. B., David, J. R., Lanzaro, G. C., and Titus, R. G. (2001). Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J. Immunol. 167, 5226-5230.
184. Moser, M., and Murphy, K. M. (2000). Dendritic cell regulation of TH1TH2 development. Nat. Immunol. 1, 199-205.
185. Mukherjee, M., Bhattacharyya, A., and Duttagupta, S. (2002). Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin. Med. Sci. Monit. 8, 117-122.
186. Müller, I., Fruth, U., and Louis, J. A. (1992). Immunobiology of experimental leishmaniasis. Med. Microbiol. Immunol. 181, 1-12.
187. Murray, H. W., and Cartelli, D. M. (1983). Killing of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence for oxygen-dependent and independent leishmanicidal activity. J. Clin. Invest. 72, 32-44.
188. Murray, H. W., Rubin, B. Y., and Rothermel, C. D. (1983). Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J. Clin. Invest. 72, 1506-1510.
189. Murray, H. W., Squires, K. E., Miralles, C. D., Stoeckle, M. Y., Granger,A. M., Granelli-Piperno, A., and Bogdan, C. (1992). Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J. Immunol. 148, 1858-1863.
190. Murugaiyan, G., Mittal, A., LopezDiego, R., Maier, L. M., Anderson, D. E., and Weiner, H. L. (2009). IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J. Immunol. 183, 2435-2443.
191. Musa, A. M., Khalil, E. A., Mahgoub, F. A., Elgawi, S. H., Modabber, F., Elkadaru, A. E., Aboud, M. H., Noazin, S., Ghalib, H. W., and El-Hassan, A. M. (2008). Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans. R. Soc. Trop. Med. Hyg. 102, 58-63.
192. Nadim, A., Javadian, E., TahvildarBidruni, G., and Ghorbani, M. (1983). Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull. Soc. Pathol. Exot. Filiales 76, 377-383.
193. Nagill, R., and Kaur, S. (2010). Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Vaccine 28, 4002-4012.
194. Nakhasi, H. L., Zheng, D., Callahan, L., Dave, J. R., and Liu, T. Y. (1989). Rubella virus: mechanism of attenuation in the vaccine strain (HPV77). Virus Res. 13, 231-243.
195. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., and Lanzavecchia, A. (2005). Selected Toll like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769-776.
196. Nateghi Rostami, M., Keshavarz Valian, H., Eskandari, S. E., Miramin Mohammadi, A., Shahrestani, S. T., Sarraf-Nejad, A., and Khamesipour, A. (2010). Differential in vitro CD4+/CD8+ T-cell response to live vs. killed Leishmania major. Parasite Immunol. 32, 101-110.
197. Nicolas, L., Prina, E., Lang, T., and Milon, G. (2002). Real-time PCR for detection and quantitation of Leishmania in mouse tissues. J. Clin. Microbiol. 40, 1666-1669.
198. Nieto, A., Domínguez-Bernal, G., Orden, J. A., De La Fuente, R., Madrid-Elena, N., and Carrión, J. (2011). Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus syrian hamster model. Vet. Res. 42, 39.
199. Nogueira, F. S., Moreira, M. A., BorjaCabrera, G. P., Santos, F. N., Menz, I., Parra, L. E., Xu, Z., Chu, H. J., Palatnik-de-Sousa, C. B., and Luvizotto, M. C. (2005). Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23, 4805-4810.
200. Nylén,S.,andAkuffo,H. (2009). Tracing immunity to human leishmaniasis. Future Microbiol. 4, 241-254.
201. Nylén, S., Maasho, K., Söderstrom, K., Ilg, T., and Akuffo, H. (2003). Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin. Exp. Immunol. 131, 457-467.
202. Nylén, S., Maurya, R., Eidsmo, L., Manandhar, K. D., Sundar, S., and Sacks, D. (2007). Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J. Exp. Med. 204, 805-817.
203. Okwor, I., and Uzonna, J. (2008). Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol. Res. 41, 123-136.
204. Olivier, M., Gregory, D. J., and Forget, G. (2005). Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view Clin. Microbiol. Rev. 18, 293-305.
205. Ozbilge, H., Aksoy, N., Gurel, M. S., and Yazar, S. (2006). IgG and IgG subclass antibodies in patients with active cutaneous leishmaniasis. J. Med. Microbiol. 55, 1329-1331.
206. Palatnik de Sousa, C. B., Moreno, M. B., Paraguai de Souza, E., and Borojevic, R. (1994a). The FML-vaccine (Fucose-Mannose Ligand) protects hamsters from experimental KalaAzar. J. Braz. Assoc. Adv. Sci. 46, 290-296.
207. Palatnik de Sousa, C. B., Paraguai de Souza, E., Gomes, E. M., and Borojevic, R. (1994b). Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML). Braz. J. Med. Biol. Res. 27, 547-555.
208. Palatnik de Sousa, C. B., Gomes, E. M., de Souza, E. P., dos Santos, W. R., de Macedo, S. R., de Medeiros, L. V., and Luz, K. (1996). The FML (fucose mannose ligand) of Leishmania donovani: a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar. Rev. Soc. Bras. Med. Trop. 29, 153-163.
209. Palatnik de Sousa, C. B., Santos, W. R., Casas, C. P., Paraguai de Souza, E., Tinoco, L. W., da Silva, B. P., Palatnik, M., and Parente, J. P. (2004). Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins. Vaccine 22, 2470-2479.
210. Papadopoulou, B., Roy, G., Breton, M., Kündig, C., Dumas, C., Fillion, I., Singh, A. K., Olivier, M., and Ouellette, M. (2002). Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun. 70, 62-68.
211. Paraguai-de-Souza, E., Bernardo, R. R., Palatnik, M., and Palatnik-deSousa, C. B. (2001). Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 19, 3104-3115.
212. Parra, L. E., Borja-Cabrera, G. P., Santos, F. N., Souza, L. O., Palatnikde-Sousa, C. B., and Menz, I. (2007). Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25, 2180-2186.
213. Pearson, R. D., and Sousa, A. Q. (1996). Clinical spectrum of leishmaniasis. Clin. Infect. Dis. 22, 1-13.
214. Perumal, D., Lim, C. S., Sakharkar, K. R., and Sakharkar, M. K. (2007). Differential genome analyses of metabolic enzymes in Pseudomonas aeruginosa for drug target identification. In Silico Biol. 7, 453-465.
215. Peters, N., and Sacks, D. (2006). Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol. Rev. 213, 159-179.
216. Petzl-Erler, M. L., Belich, M. P., and Queiroz-Telles, F. (1991). Association of mucosal leishmaniasis with HLA. Hum. Immunol. 32, 254-260.
217. Piccioli, D., Sbrana, S., Melandri, E., and Valiante, N. M. (2002). Contactdependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195,335-341.
218. Pitta, M. G., Romano, A., Cabantous, S., Henri, S., Hammad, A., Kouriba, B., Argiro, L., el Kheir, M., Bucheton, B., Mary, C., El-Safi, S. H., and Dessein, A. (2009). IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J. Clin. Invest. 119, 2379-2387.
219. Praveena,A.,Sindhuja,R.,Anuradha,V., and Habeeb, S. K. M. (2011). Putative drug target identification for chlamydia trachomatis: an in silico proteome analysis. Int. J. Biomed. Res. 2, 151-160.
220. Prina, E., Abdi, S. Z., Lebastard, M., Perret, E, Winter, N., and Antoine, J. C. (2004). Dendritic cells as host cells for the promastigote and amastigote stages of Leishmania amazonensis: the role of opsonins in parasite uptake and dendritic cell maturation. J. Cell. Sci. 117, 315-325.
221. Rachamim, N., and Jaffe, C. L. (1993). Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150, 2322-2331.
222. Rafati, S., Zahedifard, F., and Nazgouee, F. (2006). Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24, 2169-2175.
223. Raman, V. S., Bhatia, A., Picone, A., Whittle, J., Bailor, H. R., O'Donnell, J., Pattabhi, S., Guderian, J. A., Mohamath, R., Duthie, M. S., and Reed, S. G. (2010). Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J. Immunol. 185, 1701-1710.
224. Ravindran, R., Anam, K., Bairagi, B. C., Saha, B., Pramanik, N., Guha, S. K., Goswami, R. P., Banerjee, D., and Ali, N. (2004). Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect. Immun. 72, 863-870.
225. Ravindran, R., Bhowmick, S., Das, A., and Ali, N. (2010). Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. BMC Microbiol. 10, 181. doi:10.1186/1471-2180-10-181
226. Ravindran, R., Maji, M., and Ali, N. (2012). Vaccination with liposomal leishmanial antigens adjuvanted with MPL-TDM confers long-term protection against visceral leishmaniasis through human adminstrable route. Mol. Pharm. 9, 59-70.
227. Reed, S. G., Coler, R. N., and Campos-Neto, A. (2003). Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev. Vaccines 2, 239-252.
228. Remer, K. A., Apetrei, C., Schwarz, T., Linden, C., and Moll, H. (2007). Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice. Eur. J. Immunol. 37, 2463-2473.
229. Resende, D. M., Caetano, B. C., Dutra, M. S., Penido, M. L., Abrantes, C. F., Verly, R. M., Resende, J. M., Piló-Veloso, D., Rezende, S. A., Bruna-Romero, O., Fernandes, A. P., and Gazzinelli, R. T. (2008). Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells. Vaccine 26, 4585-4593.
230. Rohtagi, A., Agarwal, S. K., Bose, M., Chattopadhya, D., and Saha, K. (1996). Blood, bone marrow and splenic lymphocyte subset profiles in Indian visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 90, 431-434. Russo, D. M., Jardim, A, Carvalho, E. M., Sleath, P. R., Armitage, R. J., Olafson, R. W., and Reed, S. G. (1993). Mapping human T cell epitopes in Leishmania gp63. Identification of cross-reactive and speciesspecific epitopes. J. Immunol. 150, 932-939.
231. Russo, D. M., Jardim, A, Carvalho, E. M., Sleath, P. R., Armitage, R. J., Olafson, R. W., and Reed, S. G. (1993). Mapping human T cell epitopes in Leishmania gp63. Identification of cross-reactive and speciesspecific epitopes. J. Immunol. 150, 932-939.
232. Ryan, J. R., Smithyman, A. M., Rajasekariah, G. H., Hochberg, L., Stiteler, J. M., and Martin, S. K. (2002). Enzyme-linked immunosorbent assay based on soluble promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera from cases of visceral and cutaneous leishmaniasis. J. Clin. Microbiol. 40, 1037-1043.
233. Sachdeva, R., Banerjea, A. C., Malla, N., and Dubey, M. L. (2009). Immunogenicity and efficacy of single antigen Gp63, polytope and polytope HSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model. PLoS One 4, e7880.
234. Sacks, D. L. (2001). Leishmania-sand fly interactions controlling speciesspecific vector competence. Cell. Microbiol. 3, 189-196.
235. Sacks, D. L., Lal, S. L., Shrivastava, S. N., Blackwell, J., and Neva, F. A. (1987). An analysis of T cell responsiveness in Indian kala-azar. J. Immunol. 138, 908-913.
236. Saha, S., Mondal, S., Banerjee, A., Ghose, J, Bhowmick, S., and Ali, N. (2006). Immune responses in kala-azar. Indian J. Med. Res. 123, 245-266.
237. Saha, S., Mondal, S., Ravindran, R., Bhowmick, S., Modak, D., Mallick, S., Rahman, M., Kar, S., Goswami, R., Guha, S. K., Pramanik, N., Saha, B., and Ali, N. (2007). IL-10and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J. Immunol. 179, 5592-5603.
238. Sakharkar, K. R., Sakharkar, M. K., and Chow, V. T. K. (2004). A novel genomics approach for the identification of drug targets in pathogens, with special reference to Pseudomonas aeruginosa. In silico Biol. (Gedrukt) 4, 0028.
239. Saldarriaga, O. A., Travi, B. L., Park, W., Perez, L. E., and Melby, P. C. (2006). Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 24, 1928-1940.
240. Samant, M., Gupta, R., Kumari, S., Misra, P., Khare, P., Kushawaha, P. K., Sahasrabuddhe, A. A., and Dube, A. (2009). Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. J. Immunol. 183, 470-479.
241. Sanabria,M. X.,Vargas-Inchaustegui,D. A., Xin, L., and Soong, L. (2008). Role of natural killer cells in modulating dendritic cell responses to Leishmania amazonensis infection. Infect. Immun. 76, 5100-5109.
242. Santos, W. R., de Lima, V. M., de Souza, E. P., Bernardo, R. R., Palatnik, M., and Palatnik de Sousa, C. B. (2002). Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21, 30-43.
243. Santos, W. R., Paraguai de Souza, E., Palatnik, M., and Palatnik de Sousa, C. B. (1999). Vaccination of Swiss albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine 17, 2554-2561.
244. Saraiva, E. M., de Figueiredo Barbosa, A., Santos, F. N., BorjaCabrera, G. P., Nico, D., Souza, L. O., de Oliveira Mendes-Aguiar, C., de Souza, E. P., Fampa, P., Parra, L. E., Menz, I., Dias, J. G. Jr., de Oliveira, S. M., and Palatnikde-Sousa, C. B. (2006). The FMLvaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 24, 2423-2431.
245. Scharton, T. M., and Scott, P. (1993). Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178, 567-577.
246. Scott, P. (2003). Development and regulation of cell mediated immunity in experimental leishmaniasis. Immunol. Res. 27, 489-498.
247. Selvapandiyan, A., Dey, R., Nylen, S., Duncan, R., Sacks, D., and Nakhasi, H. L. (2009). Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J. Immunol. 183, 1813-1820.
248. Shadab, M., and Ali, N. (2011). Evasion of host defence by Leishmania donovani: subversion of signaling pathways. Mol. Biol. Int. 2011, 343961.
249. Sharifi, I., Fekri, A. R., Aflatonian, M. R., Khamesipour, A., Nadim, A., Mousavi, M. R., Momeni, A. Z., Dowlati, Y., Godal, T., Zicker, F., Smith, P. G., and Modabber, F. (1998). Randomised vaccine trial of single dose of killed L. major plus BCG against anthroponotic cutaneous leishmanisis in Bam, Iran. Lancet 351, 1540-1543.
250. Sharma, A., and Madhubala, R. (2009). Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and resistant strains of Leishmania donovani. J. Immunol. 183, 7719-7731.
251. Sharma, M. C., Gupta, A. K., Das, V. N., Verma, N., Kumar, N., Saran, R., and Kar, S. K. (2000). Leishmania donovani in blood smears of asymptomatic persons. Acta Trop. 76, 195-196.
252. Silvestre, R., Cordeiro-Da-Silva, A., Santarém, N., Vergnes, B., Sereno, D., and Ouaissi, A. (2007). SIR2deficient Leishmania infantum induces a defined IFN-gamma/IL10 pattern that correlates with protection. J. Immunol. 179, 3161-3170.
253. Sinha, S., Sundaram, S., Singh, A. P., and Tripathi, A. (2011). A gp63 based vaccine candidate against visceral leishmaniasis. Bioinformation 5, 320-325.
254. Skeiky, Y. A., Coler, R. N., Brannon, M., Stromberg, E., Greeson, K., Crane, R. T., Webb, J. R., Campos-Neto, A., and Reed, S. G. (2002). Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20, 3292-3303.
255. Soto, M., Requena, J. M., Quijada, L., Perez, M. J., Nieto, C. G., Guzman, F., Patarroyo, M. E., and Alonso, C.(1999). Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis. Clin. Exp. Immunol. 115, 342-349.
256. Späth, G. F., Epstein, L., Leader, B., Singer, S. M., Avila, H. A., Turco, S. J., and Beverley, S. M. (2000). Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc. Natl. Acad. Sci. U.S.A. 97, 9258-9263.
257. Spitzer, N., Jardim, A., Lippert, D., and Olafson, R. W. (1999). Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 17, 1298-1300.
258. Squires, K. E., Rosenkaimer, F., Sherwood, J. A., Forni, A. L., Were, J. B., and Murray, H. W. (1993). Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. Am. J. Trop. Med. Hyg. 48, 666-669.
259. Stäger, S., Alexander, J., Kirby, A. C., Botto, M., Rooijen, N. V., Smith, D. F., Brombacher, F., and Kaye, P. M. (2003). Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat. Med. 9, 1287-1292.
260. Stager, S., Smith, D. F., and Kaye, P. M. (2000). Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165, 7064-7071.
261. Stern, A. S., Podlaski, F. J., Hulmes, J. D., Pan, Y. C., Quinn, P. M., Wolitzky, A. G., Familletti, P. C., Stremlo, D. L., Truitt, T., Chizzonite, R., and Gately, M. K. (1990). Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. U.S.A. 87, 6808-6812.
262. Stobie, L., Gurunathan, S., Prussin, C., Sacks, D. L., Glaichenhaus, N., Wu, C.-Y., and Seder, R. A. (2000). The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. U.S.A. 97, 8427-8432.
263. Sukumaran, B., Tewary, P., Saxena, S., and Madhubala, R. (2003). Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21, 1292-1299.
264. Sundar, S., and Murray, H. W. (1995). Effect of treatment with interferongamma alone in visceral leishmaniasis. J. Infect. Dis. 172, 1627-1629.
265. Sundar, S., Reed, S. G., Sharma, S., Mehrotra, A., and Murray, H. W. (1997a). Circulating T helper 1 (Th1) celland Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56, 522-525.
266. Sundar, S., Singh, V. P., Sharma, S., Makharia, M. K., and Murray, H. W. (1997b). Response to interferongamma plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis. 176, 1117-1119.
267. Sundar, S., Rosenkaimer, F., Lesser, M. L., and Murray, H. W. (1995). Immunochemotherapy for a systemic intracellular infection: accelerated response using interferongamma in visceral leishmaniasis. J. Infect. Dis. 171, 992-996.
268. Sundar, S., Rosenkaimer, F., and Murray, H. W. (1994). Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J. Infect. Dis. 170, 659-662.
269. Tejle, K., Lindroth, M., Magnusson, K. E., and Rasmusson, B. (2008). Wild-type Leishmania donovani promastigotes block maturation, increase integrin expression and inhibit detachment of human monocyte-derived dendritic cells the influence of phosphoglycans. FEMS Microbiol. Lett. 279, 92-102.
270. Tewary, P., Jain, M., Sahani, M. H., Saxena, S., and Madhubala, R. (2005). A heterologous primeboost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J. Infect. Dis. 191, 2130-2137.
271. Tewary, P., Pandya, J., Mehta, J., Sukumaran, B., and Madhubala, R. (2004a). Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection. FEMS Immunol. Med. Microbiol. 4, 241-248.
272. Tewary, P., Sukumaran, B., Saxena, S., and Madhubala, R. (2004b). Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen. Vaccine 22, 3053-3060.
273. Titus, R. G., and Ribeiro, J. M. (1988). Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 239, 1306.
274. Tonui, W. K., Mbati, P. A., Anjili, J. O., Orago,A. S.,Turco,S. J.,Githure,J. I., and Koech, D. K. (2001). Transmission blocking vaccine studies in lelishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis. East Afr. Med. J. 78, 84-89.
275. Tracey, K. J., Wei, H., Manogue, K. R., Fong, Y., Hesse, D. G., Nguyen, H. T., Kuo, G. C., Beutler, B., Cotran, R. S., Cerami, A., and Lowry, S. F. (1988). Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 167, 1211-1227.
276. Trinchieri, G. (1993). Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today 14, 335-338.
277. Tsagozis, P., Karagouni, E., and Dotsika,E. (2004). Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis. Int. J. Immunopathol. Pharmacol. 17, 343-352.
278. Valenzuela, J. G., Garfield, M., Rowton, E. D., and Pham, V. M. (2004). Identification of the most abundant secreted proteins from the salivary glands of the sand fly Lutzomyia longipalpis,vectorofLeishmania chagasi. J. Exp. Biol. 7, 3717-3729.
279. Vélez, I. D., Gilchrist, K.,Arbelaez, M. P., Rojas, C. A., Puerta, J. A., Antunes, C. M., Zicker, F., and Modabber, F. (2005). Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans. R. Soc. Trop. Med. Hyg. 99, 593-598.
280. Vélez, I. D., Gilchrist, K., Martínez, S., Ramírez-Pineda, J. R., Ashman, J. A., Alves, F. P., Coler, R. N., Bogatzki, L. Y., Kahn, S. J., Beckmann, A. M., Cowgill, K. D., Reed, S. G., and Piazza, F. M. (2009). Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28, 329-337.
281. Vinet, A. F., Fukuda, M., Turco, S. J., and Descoteaux, A. (2009). The Leishmania donovani lipophosphoglycan excludes the vesicular proton-ATPase from phagosomes by impairing the recruitment of synaptotagmin V. PLoS Pathog. 5, e1000628. doi:10.1371/journal.ppat. 1000628
282. Vouldoukis, I., Bécherel, P. A., Riveros-Moreno, V., Arock, M., da Silva, O., Debré, P., Mazier, D., and Mossalayi, M. D. (1997). Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur. J. Immunol. 4, 860-865.
283. Walker, P. S., Scharton-Kersten, T., Krieg, A. M., Love-Homan, L., Rowton, E. D., Udey, M. C., and Vogel, J. C. (1999). Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12and IFN-?-dependent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 96, 6970-6975.
284. Walton, B. C., and Valverde, L. (1979). Racial difference in espundia. Ann. Trop. Med. Parasitol. 73, 23-29.
285. Wang, Y., Chen, Y., Xin, L., Beverley, S. M., Carlsen, E. D., Popov, V., Chang, K. P., Wang, M., and Soong, L. (2011). Differential microbicidal effects of human histone proteins H2A and H2B on Leishmania promastigotes and amastigotes. Infect. Immun. 79, 1124-1133.
286. Weigle, K., and Saravia, N. G. (1996). Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous leishmaniasis. Clin. Dermatol. 14, 433-450.
287. Wilson, M. E., Jeronimo, S. M., and Pearson, R. D. (2005). Immunopathogenesis of infection with the visceralizing Leishmania species. Microb. Pathog. 38, 147-160.
288. Woelbing, F., Kostka, S. L., Moelle, K., Belkaid, Y., Sunderkoetter, C., Verbeek, S., Waisman, A., Nigg, A. P., Knop, J., Udey, M. C., and von Stebut, E. (2006). Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J. Exp. Med. 203, 177-188.
289. Wu, W., Huang, L., and Mendez, S. (2010). A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur. J. Immunol. 40, 2517-2527.
290. Yam, K. K., Hugentobler, F., Pouliot, P., Stern, A. M., Lalande, J. D., Matlashewski, G., Olivier, M., and Cousineau, B. (2011). Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. J. Med. Microbiol. 60, 1248-1260.
291. Zadeh-Vakili, A., Taheri, T., Taslimi, Y., Doustdari, F., Salmanian, A. H., and Rafati, S. (2004). Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine 22, 1930-1940.
292. Zambrano-Villa, S., Borjas, D., Carrero, J., and Ortiz-Ortiz, L. (2002). How protozoan parasites evade the immune response. Trends Parasitol. 18, 272-278.
293. Zhu, Q., Egelston, C., Vivekanandhan, A., Uematsu, S., Akira, S., Klinman, D. M.,Belyakov,I. M.,and Berzofsky, J. A. (2008). Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc. Natl. Acad. Sci. U.S.A. 105, 16260-16265.
294. Zijlstra, E. E., el-Hassan, A. M., Ismael, A., and Ghalib, H. W. (1994). Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am. J. Trop. Med. Hyg. 51, 826-836.
295. Zwingenberger, K., Harms, G., Pedrosa, C., Omena, S., Sandkamp, B., and Neifer, S. (1990). Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferongamma production. Clin. Immunol. Immunopathol. 57, 242-249.